Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(23 sites)
United States
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California UCLA Hematology/Oncology, Westwood, Los Angeles, California Sarah Cannon Research Institute at Health ONE, Denver, Colorado Yale Cancer Center, New Haven, Connecticut Moffitt Cancer Center, Tampa, Florida Roswell Park, Buffalo, New York Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York, New York Columbia University Medical Center, New York, New York Memorial Slone Kettering Cancer Center, New York, New York UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania SCRI Oncology Partners, Nashville, Tennessee Vanderbilt-Ingram Cancer Center, Nashville, Tennessee NEXT Oncology - Austin, Austin, Texas NEXT Oncology - Dallas, Dallas, Texas MD Anderson Cancer Center, Houston, Texas START Moutain Region, West Valley City, Utah NEXT Oncology - Virginia, Fairfax, Virginia Australia
The Kinghorn Cancer Center, St. Vincent's Health Network, Darlinghurst, New South Wales Scientia Clinical Research, Ltd, Randwick, New South Wales Gallipoli Medical Research Centre- Greenslopes Private Hospital, Greenslopes, Queensland Southern Oncology Research Unit, Adelaide, South Australia Cabrini Health Limited, Malvern, Victoria Cabrini Hospital, Malvern, Victoria